Metsera, Inc. (MTSR) Stock

About Metsera, Inc.

Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.

Metsera, Inc. is headquartered in US.

Metsera, Inc. (MTSR) stock trades at $70.50 with a market capitalization of $7.43B. The stock is valued at a price-to-earnings (P/E) ratio of -28.09, price-to-book of 21.96, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.30 and $83.86, and currently trades 15.9% below its 52-week high.

On profitability, Metsera, Inc. generates a return on equity (ROE) of -60.74%, return on capital employed of -59.46%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: metsera.com